Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Work In Process (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Work In Process data on record, last reported at $7.3 million in Q4 2025.

  • For Q4 2025, Work In Process fell 27.18% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $7.3 million, down 27.18%, while the annual FY2025 figure was $7.3 million, 27.18% down from the prior year.
  • Work In Process reached $7.3 million in Q4 2025 per MRVI's latest filing, down from $9.7 million in the prior quarter.
  • Across five years, Work In Process topped out at $30.6 million in Q3 2022 and bottomed at $7.3 million in Q4 2025.
  • Average Work In Process over 5 years is $16.8 million, with a median of $13.6 million recorded in 2023.
  • Peak YoY movement for Work In Process: skyrocketed 30.73% in 2022, then plummeted 60.06% in 2023.
  • A 5-year view of Work In Process shows it stood at $21.4 million in 2021, then grew by 2.66% to $22.0 million in 2022, then crashed by 42.23% to $12.7 million in 2023, then fell by 20.74% to $10.0 million in 2024, then dropped by 27.18% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $7.3 million in Q4 2025, $9.7 million in Q3 2025, and $10.5 million in Q2 2025.